GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor
US-2024294493-A1 · Sep 5, 2024 · US
Compositions and methods for inhibiting leishmania
US9901569B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9901569-B2 |
| Application number | US-201514924605-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 27, 2015 |
| Priority date | Oct 30, 2014 |
| Publication date | Feb 27, 2018 |
| Grant date | Feb 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts.
First claim
Opening claim text (preview).
What is claimed as new and desired to be protected by Letters Patent of the United States is: 1. A method of reducing the Leishman-Donovan units (LDU) of Leishmaniasis in a host, comprising: administering a daily dose of at least about 0.1 mg/kg of an autophagy inducer (AI) to the host wherein the AI is AR-12 (2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide) and is co-administered with a second compound, and the Leishman-Donovan units (LDU) of Leishmaniasis in the host of Leishmaniasis are reduced. 2. The method of claim 1 , wherein the Leishman-Donovan units (LDU) are reduced to less than about 47% of the untreated control. 3. The method of claim 1 , wherein the second compound is selected from the group consisting of sodium stibogluconate (SSG), amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole. 4. The method of claim 3 , wherein the resulting Leishman-Donovan units (LDU) is less than about 1% of the untreated control. 5. A method of treating a host infected with Leishmaniasis, comprising: administering a daily dose of at least about 0.1 mg/kg of an autophagy inducer (AI) and a second compound to the host, wherein the AI is AR-12 (2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide). 6. The method of claim 5 , wherein the second compound is selected from the group consisting of sodium stibogluconate (SSG), amphotericin B, pentamidine isethionate, miltefosine, ketoconazole, itraconazole, and fluconazole.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/415Primary
1,2-Diazoles · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9901569B2 cover?
- Compositions and methods for inhibiting Leishmaniasis using AIs are provided. Aspects provide compositions and methods for administering AIs alone or in combination with other compounds to infected hosts.
- Who is the assignee on this patent?
- Ohio State Innovation Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K31/415. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).